Paul T. Quinlan
Known title: General CounselCIK: 0001333277
Associated companies
Transaction History
| ORKA | ▲ Buy | Option Exercise | 10,000 | $78K | 9/21/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 2,900 | $268K | 9/21/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 3,832 | $358K | 9/21/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 601 | $57K | 9/21/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 2,667 | $254K | 9/21/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 1,039 | $99K | 9/15/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 10,000 | $78K | 8/14/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 42,000 | $525K | 8/14/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 3,630 | $385K | 8/14/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 10,434 | $1.1M | 8/14/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 14,696 | $1.6M | 8/14/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 10,200 | $1.1M | 8/14/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 9,193 | $1.0M | 8/14/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 3,847 | $428K | 8/14/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 733 | $51K | 6/15/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 733 | $30K | 3/16/2026 | View on chart |
| ORKA | ▲ Buy | Grant | 32,500 | $0 | 1/23/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka
HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.